Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Goodwill (2021 - 2024)

Barinthus Biotherapeutics (BRNS) has disclosed Goodwill for 4 consecutive years, with $12.2 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Goodwill changed 0.0% year-over-year to $12.2 million, compared with a TTM value of $12.2 million through Jun 2024, changed 0.0%, and an annual FY2023 reading of $12.2 million, changed 0.0% over the prior year.
  • Goodwill was $12.2 million for Q2 2024 at Barinthus Biotherapeutics, roughly flat from $12.2 million in the prior quarter.
  • Across five years, Goodwill topped out at $12.6 million in Q4 2021 and bottomed at $12.2 million in Q4 2022.
  • Average Goodwill over 4 years is $12.4 million, with a median of $12.2 million recorded in 2022.
  • The sharpest move saw Goodwill dropped 3.33% in 2022, then changed 0.0% in 2023.
  • Year by year, Goodwill stood at $12.6 million in 2021, then decreased by 3.33% to $12.2 million in 2022, then changed by 0.0% to $12.2 million in 2023, then changed by 0.0% to $12.2 million in 2024.
  • Business Quant data shows Goodwill for BRNS at $12.2 million in Q2 2024, $12.2 million in Q4 2023, and $12.2 million in Q3 2023.